Heparin Based on Ideal Body Weight for Cardiopulmonary Bypass in Obese Patients (HEPOIRINE)
Cardiac Surgery, Cardiopulmonary Bypass, Obese Patients (BMI ≥ 30 kg/m²)
About this trial
This is an interventional treatment trial for Cardiac Surgery
Eligibility Criteria
Inclusion criteria:
- Obese patients (BMI ≥ 30 kg/m²)
- Planned cardiac surgery under cardiopulmonary bypass
- Coronary-artery bypass graft, or valve surgery)
- Age ≥ 18 yo
Exclusion criteria:
- Allergy to heparin
- Emergency surgical intervention
- Redo surgery
- Heart transplantation
- Surgery for circulatory assistance
- Pre-operative heparin use
Sites / Locations
- Hôpitaux Universitaires de StrasbourgRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Intervention group
Control group
Obese patients, randomized to receive an initial IV bolus of Heparin, before beginning of the cardiopulmonary bypass, at the dosage of 340 UI/kg based on ideal body weight of the obese patients. The objective is to obtain an ACT target ≥ 400 s before the beginning of CPB. If necessary, additional boluses of heparin are administered at the dose of 100 UI/kg based on ideal body weight, to maintain this target during the CPB.
Obese patients, randomized to receive an initial IV bolus of Heparin, before beginning of the cardiopulmonary bypass, at the usual dosage of 300 UI/kg based on total body weight of the obese patients. The objective is to obtain an ACT target ≥ 400 s before the beginning of CPB. If necessary, additional boluses of heparin are administered at the dose of 100 UI/kg based on total body weight, to maintain this target during the CPB.